Previous close | 2.4200 |
Open | 2.4800 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 2.4800 - 2.5700 |
52-week range | 1.8100 - 3.5700 |
Volume | |
Avg. volume | 9,377 |
Market cap | 207.764M |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1000 |
Earnings date | 10 May 2024 - 18 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.43 |
MARSEILLE, France, May 07, 2024--Innate Pharma announces conference call and webcast for Q1 business update
MARSEILLE, France, April 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia and hig
MARSEILLE, France, April 15, 2024--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024